Clinical trial
Efficacy of CC-5013 (Revlimid or Lenalidomide) in Patients With Primary Systemic…
NCT00166413 · Mayo Clinic, Other · Completed
Key facts
| NCT number | NCT00166413 |
|---|---|
| Title | Efficacy of CC-5013 (Revlimid or Lenalidomide) in Patients With Primary Systemic Amyloidosis |
| Official title | A Phase II Trial of CC-5013 in Patients With Primary Systemic Amyloidosis |
| Lead sponsor | Mayo Clinic, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Amyloidosis |
| Intervention type | Drug |
| Interventions | CC-5013 |
| Enrollment | 38 |
| Start date | Apr 1, 2005 |
| Primary completion | Dec 1, 2006 |
| First posted | Sep 14, 2005 |
| Last update posted | May 6, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: